CD19 and diffuse large B-cell lymphoma: Yescarta, a second CD19-specific CAR-T product, was approved on October 18, 2017, for adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), including diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL), and transformed follicular lymphoma (TFL), after two or more lines of systemic therapy (39).